Andreas Rimner

List of Publications by Year
in descending order

152 papers	6,189 citations	81839 39 h-index	85498 71 g-index
153 all docs	153 docs citations	153 times ranked	6843 citing authors

#	Article	IF	Citations
1	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 1301-1311.	0.8	445
2	Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Practical Radiation Oncology, 2017, 7, 295-301.	1.1	339
3	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1343-1373.	0.8	324
4	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. Journal of Thoracic Oncology, 2021, 16, 860-867.	0.5	323
5	Thymic carcinoma outcomes and prognosis: Results of an international analysis. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 95-101.e2.	0.4	190
6	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.3	168
7	Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 2016, 34, 2761-2768.	0.8	154
8	Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer. Nature Reviews Clinical Oncology, 2021, 18, 547-557.	12.5	152
9	Definitive and Adjuvant Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Journal of Clinical Oncology, 2015, 33, 2100-2105.	0.8	150
10	Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1278-1283.	0.4	142
11	Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1357-1366.	0.4	134
12	Radiomics analysis of pulmonary nodules in low‐dose <scp>CT</scp> for early detection of lung cancer. Medical Physics, 2018, 45, 1537-1549.	1.6	104
13	Tumor-Aware, Adversarial Domain Adaptation from CT to MRI for Lung Cancer Segmentation. Lecture Notes in Computer Science, 2018, 11071, 777-785.	1.0	104
14	Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiation Oncology, 2020, 15, 214.	1.2	103
15	Local Control and Toxicity in a Large Cohort of Central Lung Tumors Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1168-1176.	0.4	98
16	Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 103-109.e2.	0.4	96
17	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute, 2019, 111, 575-583.	3.0	96
18	Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 322-329.	0.4	91

#	Article	IF	Citations
19	Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2017, 98, 409-418.	0.4	87
20	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology, 2018, 13, 1655-1667.	0.5	85
21	A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 935-944.	0.4	83
22	Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma—An Analysis of the International Thymic Malignancies Interest Group Retrospective Database. Journal of Thoracic Oncology, 2016, 11, 1785-1792.	0.5	82
23	The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology, 2019, 14, 1172-1183.	0.5	60
24	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. Cancer Immunology Research, 2019, 7, 1047-1053.	1.6	59
25	Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer: Implications for Surveillance. Clinical Lung Cancer, 2016, 17, 177-183.e2.	1.1	57
26	A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 362-373.e8.	0.4	57
27	Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. International Journal of Radiation Oncology Biology Physics, 2014, 90, 394-401.	0.4	55
28	Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. International Journal of Radiation Oncology Biology Physics, 2021, 110, 35-52.	0.4	54
29	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS ONE, 2017, 12, e0182665.	1.1	54
30	Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors. Radiotherapy and Oncology, 2014, 112, 267-271.	0.3	53
31	FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer. Lung Cancer, 2015, 89, 115-120.	0.9	53
32	Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, 993-1000.	0.5	53
33	Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. European Journal of Cardio-thoracic Surgery, 2016, 50, 766-771.	0.6	52
34	Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC). Acta Oncológica, 2018, 57, 1567-1573.	0.8	51
35	Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. Journal of Clinical Investigation, 2019, 129, 786-801.	3.9	50
36	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research, 2017, 23, 7483-7489.	3.2	48

#	Article	IF	Citations
37	The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors. Journal of Thoracic Oncology, 2020, 15, 436-447.	0.5	46
38	Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh. Cancer, 2009, 115, 149-157.	2.0	43
39	Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 138-145.	0.4	43
40	Cross‐modality (CT‐MRI) prior augmented deep learning for robust lung tumor segmentation from small MR datasets. Medical Physics, 2019, 46, 4392-4404.	1.6	42
41	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.4	40
42	Clinical outcomes, local‐regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiotherapy and Oncology, 2020, 149, 205-211.	0.3	39
43	Failure Patterns Relative to Radiation Treatment Fields for Stage II‐IV Thymoma. Journal of Thoracic Oncology, 2014, 9, 403-409.	0.5	38
44	Cardio-pulmonary substructure segmentation of radiotherapy computed tomography images using convolutional neural networks for clinical outcomes analysis. Physics and Imaging in Radiation Oncology, 2020, 14, 61-66.	1.2	38
45	Pathogenic *ATM* Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	3.0	38
46	Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation. Radiotherapy and Oncology, 2017, 125, 130-135.	0.3	37
47	Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab. Cancer Medicine, 2020, 9, 4622-4631.	1.3	37
48	Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer, 2017, 108, 109-114.	0.9	36
49	Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Advances in Radiation Oncology, 2017, 2, 548-554.	0.6	36
50	Toward predicting the evolution of lung tumors during radiotherapy observed on a longitudinal MR imaging study via a deep learning algorithm. Medical Physics, 2019, 46, 4699-4707.	1.6	34
51	Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. Advances in Radiation Oncology, 2018, 3, 391-398.	0.6	33
52	A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases. Journal of Thoracic Disease, 2019, 11, 5187-5198.	0.6	32
53	Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget, 2017, 8, 77872-77882.	0.8	31
54	Predictive Treatment Management: Incorporating a Predictive Tumor Response Model Into Robust Prospective Treatment Planning for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 446-452.	0.4	30

#	Article	IF	Citations
55	Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, e253-e258.	1.1	28
56	Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?. Lancet Oncology, The, 2016, 17, e43-e44.	5.1	28
57	Toward personalized dose-prescription in locally advanced non-small cell lung cancer: Validation of published normal tissue complication probability models. Radiotherapy and Oncology, 2019, 138, 45-51.	0.3	27
58	Segmenting lung tumors on longitudinal imaging studies via a patient-specific adaptive convolutional neural network. Radiotherapy and Oncology, 2019, 131, 101-107.	0.3	27
59	Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors. Lung Cancer, 2020, 147, 45-48.	0.9	27
60	New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. Journal of Clinical Oncology, 2022, 40, 681-692.	0.8	26
61	Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. EJNMMI Research, 2016, 6, 79.	1.1	25
62	Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors. JAMA Oncology, 2019, 5, 737.	3.4	24
63	Novel radiation therapy approaches in malignant pleural mesothelioma. Annals of Cardiothoracic Surgery, 2012, 1, 457-61.	0.6	24
64	Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. Journal of Thoracic Oncology, 2017, 12, 745-751.	0.5	23
65	The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. The Lancet Digital Health, 2021, 3, e565-e576.	5.9	23
66	Automatic tracking of arbitrarily shaped implanted markers in kilovoltage projection images: A feasibility study. Medical Physics, 2014, 41, 071906.	1.6	22
67	Pharmacokinetic Analysis of Dynamic ^{18}F-Fluoromisonidazole PET Data in Nonâ€"Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 911-919.	2.8	22
68	ACR Appropriateness CriteriaÂ® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology, 2014, 28, 706-10, 712, 714 passim.	0.4	22
69	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 178-185.	1.3	21
70	Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. Radiotherapy and Oncology, 2020, 144, 101-104.	0.3	21
71	Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced ChestÂWall Pain. International Journal of Radiation Oncology Biology Physics, 2015, 93, 418-424.	0.4	20
72	Novel spirometry based on optical surface imaging. Medical Physics, 2015, 42, 1690-1697.	1.6	19

#	Article	IF	Citations
73	Computed tomographic features predictive of local recurrence in patients with early stage lung cancer treated with stereotactic body radiation therapy. Clinical Imaging, 2015, 39, 254-258.	0.8	19
74	Characterization of optical‐surface‐imaging‐based spirometry for respiratory surrogating in radiotherapy. Medical Physics, 2016, 43, 1348-1360.	1.6	19
75	Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 61-69.	0.4	19
76	Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. International Journal of Radiation Oncology Biology Physics, 2017, 97, 1066-1076.	0.4	19
77	The expanding role of radiation therapy for thymic malignancies. Journal of Thoracic Disease, 2018, 10, S2555-S2564.	0.6	19
78	Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nature Communications, 2021, 12, 4669.	5.8	19
79	Rapid estimation of 4DCT motion‐artifact severity based on 1D breathing‐surrogate periodicity. Medical Physics, 2014, 41, 111717.	1.6	18
80	Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 705-714.e1.	0.4	18
81	Quantification of accumulated dose and associated anatomical changes of esophagus using weekly Magnetic Resonance Imaging acquired during radiotherapy of locally advanced lung cancer. Physics and Imaging in Radiation Oncology, 2020, 13, 36-43.	1.2	18
82	Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy. Practical Radiation Oncology, 2021, 11, e52-e62.	1.1	18
83	Thymic Carcinomas—A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group. Journal of Thoracic Oncology, 2022, 17, 637-650.	0.5	18
84	Prognostic Value of Preradiotherapy 18F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 184-188.	1.1	17
85	Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery. Clinical Lung Cancer, 2017, 18, e161-e168.	1.1	17
86	Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2018, 106, 848-855.	0.7	17
87	Clinical evaluation of 4D MRI in the delineation of gross and internal tumor volumes in comparison with 4DCT. Journal of Applied Clinical Medical Physics, 2019, 20, 51-60.	0.8	17
88	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 2021, 159, 66-73.	0.9	17
89	Design and validation of a MV/kV imaging‐based markerless tracking system for assessing real‐time lung tumor motion. Medical Physics, 2018, 45, 5555-5563.	1.6	16
90	Validating a Predictive Atlas of Tumor Shrinkage for Adaptive Radiotherapy of Locally Advanced Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 978-986.	0.4	16

#	Article	IF	Citations
91	Dose to the cardio-pulmonary system and treatment-induced electrocardiogram abnormalities in locally advanced non-small cell lung cancer. Clinical and Translational Radiation Oncology, 2019, 19, 96-102.	0.9	16
92	Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer due to treatment-related immunosuppression?. Radiotherapy and Oncology, 2020, 143, 51-57.	0.3	16
93	A geometric atlas to predict lung tumor shrinkage for radiotherapy treatment planning. Physics in Medicine and Biology, 2017, 62, 702-714.	1.6	15
94	PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT). Clinical and Translational Radiation Oncology, 2017, 7, 91-93.	0.9	15
95	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee â€" International Association for the Study of Lung Cancer â€" Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. Journal of Thoracic Oncology, 2019, 14, 1718-1731.	0.5	15
96	Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy. Acta OncolÃ³gica, 2020, 59, 164-170.	0.8	14
97	Thoracic Radiation Therapy During Coronavirus Disease 2019: Provisional Guidelines from a Comprehensive Cancer Center within a Pandemic Epicenter. Advances in Radiation Oncology, 2020, 5, 603-607.	0.6	14
98	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. Translational Lung Cancer Research, 2007, 6, 186-195.	1.3	13
99	Toward correcting drift in target position during radiotherapy via computerâ€controlled couch adjustments on a programmable Linac. Medical Physics, 2013, 40, 051719.	1.6	13
100	Diffusionâ€weighted <scp>MRI</scp> of the lung at 3T evaluated using echoâ€planarâ€based and singleâ€shot turbo spinâ€echoâ€based acquisition techniques for radiotherapy applications. Journal of Applied Clinical Medical Physics, 2019, 20, 284-292.	0.8	13
101	Evaluation of tumor localization in respiration motionâ€corrected coneâ€beam CT: Prospective study in lung. Medical Physics, 2014, 41, 101918.	1.6	12
102	Correlation Between Tumor Metabolism and Semiquantitative Perfusion Magnetic Resonance Imaging Metrics in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 718-726.	0.4	12
103	CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors. Annals of Thoracic Surgery, 2022, 113, 957-965.	0.7	12
104	The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. Journal of Thoracic Oncology, 2021, 16, 1392-1402.	0.5	12
105	Need for Caution in the Diagnosis of Radiation Pneumonitis During the COVID-19 Pandemic. Advances in Radiation Oncology, 2020, 5, 617-620.	0.6	12
106	Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. Annals of Translational Medicine, 2017, 5, 479-479.	0.7	11
107	Palliative efficacy and local control of conventional radiotherapy for lung metastases. Annals of Palliative Medicine, 2017, 6, S21-S27.	0.5	11
108	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. JCO Oncology Practice, 2022, 18, e780-e785.	1.4	11

#	Article	IF	Citations
109	Identifying the Optimal Radiation Dose in Locally Advanced Non–Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy. Clinical Lung Cancer, 2018, 19, e131-e140.	1.1	10
110	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. Journal of Thoracic Oncology, 2019, 14, 1989-1994.	0.5	10
111	Early Prediction of Acute Esophagitis for Adaptive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 110, 883-892.	0.4	10
112	Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab. Radiotherapy and Oncology, 2022, 167, 158-164.	0.3	10
113	Palliative Radiation for Lung Cancer Metastases to the Breast: Two Case Reports. Journal of Thoracic Oncology, 2007, 2, 1133-1135.	0.5	9
114	Evaluation of automatic contour propagation in T2‐weighted 4<scp>DMRI</scp> for normal‐tissue motion assessment using internal organ‐at‐risk volume (<scp>IRV</scp>). Journal of Applied Clinical Medical Physics, 2018, 19, 598-608.	0.8	9
115	The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group. Lung Cancer, 2019, 132, 24-27.	0.9	9
116	A super‐resolution framework for the reconstruction of T2‐weighted (T2w) time‐resolved (TR) 4DMRI using T1w TR‐4DMRI as the guidance. Medical Physics, 2020, 47, 3091-3102.	1.6	9
117	Deep cross‐modality (MR‐CT) educed distillation learning for cone beam CT lung tumor segmentation. Medical Physics, 2021, 48, 3702-3713.	1.6	9
118	The value of collaboration between thoracic surgeons and radiation oncologists while awaiting evidence in operable stage i non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 429-431.	0.4	8
119	Technical Note: 3D localization of lung tumors on cone beam CT projections via a convolutional recurrent neural network. Medical Physics, 2020, 47, 1161-1166.	1.6	8
120	Enhanced super‐resolution reconstruction of T1w time‐resolved 4DMRI in low‐contrast tissue using 2‐step hybrid deformable image registration. Journal of Applied Clinical Medical Physics, 2020, 21, 25-39.	0.8	8
121	Impact of Tumor Mutational Burden and Gene Alterations Associated with Radiation-Response on Outcomes of Post-Operative Radiation Therapy in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	8
122	Radiation-Induced Dyspnea in Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy. Cancers, 2021, 13, 3734.	1.7	7
123	Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC. JTO Clinical and Research Reports, 2021, 2, 100209.	0.6	7
124	Predicting spatial esophageal changes in a multimodal longitudinal imaging study via a convolutional recurrent neural network. Physics in Medicine and Biology, 2020, 65, 235027.	1.6	7
125	Enhancement of Long-Term External–Internal Correlation by Phase-Shift Detection and Correction Based on Concurrent External Bellows and Internal Navigator Signals. Advances in Radiation Oncology, 2019, 4, 377-389.	0.6	6
126	Predictive Modeling of Thoracic Radiotherapy Toxicity and the Potential Role of Serum Alpha-2-Macroglobulin. Frontiers in Oncology, 2020, 10, 1395.	1.3	6

#	Article	IF	Citations
127	Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. Advances in Radiation Oncology, 2021, 6, 100615.	0.6	6
128	Four-Dimensional Computed Tomography-Based Correlation of Respiratory Motion of Lung Tumors With Implanted Fiducials and an External Surrogate. Advances in Radiation Oncology, 2022, 7, 100885.	0.6	6
129	Postoperative radiotherapy: Not all thymic malignancies are created equal. Cancer, 2015, 121, 972-974.	2.0	5
130	SMART or simply bold?. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 476-477.	0.4	5
131	LDeform: Longitudinal deformation analysis for adaptive radiotherapy of lung cancer. Medical Physics, 2020, 47, 132-141.	1.6	5
132	Delivering safe and effective stereotactic body radiation therapy for patients with centrally located early stage non-small cell lung cancer. Chinese Clinical Oncology, 2020, 9, 39-39.	0.4	5
133	Feasibility of MR-guided radiotherapy using beam-eye-view 2D-cine with tumor-volume projection. Physics in Medicine and Biology, 2021, 66, 045020.	1.6	5
134	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). Lung Cancer, 2022, 166, 228-241.	0.9	5
135	Quantitative assessment of target delineation variability for thymic cancers: agreement evaluation of a prospective segmentation challenge. Journal of Radiation Oncology, 2016, 5, 55-61.	0.7	4
136	Dualâ€input tracer kinetic modeling of dynamic contrastâ€enhanced MRI in thoracic malignancies. Journal of Applied Clinical Medical Physics, 2019, 20, 169-188.	0.8	4
137	Deep learning driven predictive treatment planning for adaptive radiotherapy of lung cancer. Radiotherapy and Oncology, 2022, 169, 57-63.	0.3	4
138	High- and low-dose-rate intraoperative radiotherapy for thoracic malignancies resected with close or positive margins. Brachytherapy, 2016, 15, 208-215.	0.2	3
139	Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC. JTO Clinical and Research Reports, 2021, 2, 100197.	0.6	3
140	Can bronchoscopically implanted anchored electromagnetic transponders be used to monitor tumor position and lung inflation during deep inspiration breathâ€hold lung radiotherapy?. Medical Physics, 2022, 49, 2621-2630.	1.6	3
141	Outcomes of Stage III NSCLC with occult primary vs. known primary lesions. Lung Cancer, 2019, 127, 34-36.	0.9	2
142	A Planning Comparison of IMRT vs. Pencil Beam Scanning for Deep Inspiration Breath Hold Lung Cancers. Medical Dosimetry, 2022, 47, 26-31.	0.4	2
143	Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice. Oncologist, 2022, 27, 610-614.	1.9	2
144	Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy. European Radiology, 2019, 29, 3696-3704.	2.3	1

#	Article	IF	Citations
145	Pre-treatment CT imaging in stage IIIA lung cancer: Can we predict local recurrence after definitive chemoradiotherapy?. Clinical Imaging, 2021, 69, 133-138.	0.8	1
146	What Is the Impact of Hippocampus Avoidanceâ€"Prophylactic Cranial Irradiation on Neurocognitive Preservation?. Journal of Thoracic Oncology, 2021, 16, 722-724.	0.5	1
147	Multidisciplinary Management of Thymic Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 466-470.	1.8	1
148	In Reply to Sabour. International Journal of Radiation Oncology Biology Physics, 2021, 110, 915-916.	0.4	0
149	Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer. Annals of Translational Medicine, 2020, 8, 1613-1613.	0.7	0
150	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. Cancers, 2021, 13, 5773.	1.7	0
151	Radiation Time, Dose, and Fractionation in the Treatment of Lung Cancer. Medical Radiology, 2021, , .	0.0	0
152	Optimizing Lung Cancer Radiotherapy Treatments Using Personalized Dose-Response Curves. Medical Radiology, 2022, , .	0.0	0